What is claimed is:

1. A formulation for intravenous administration to a patient suffering from cancer in order to treat the cancer, comprising:
    a. whole blood in an amount of at least 60% v/v of the formulation;
    b. at least 10 μg/mL of ABDNAZ; and
    c. an anticoagulant.
2. The formulation of claim 1, wherein the formulation further comprises polyethylene glycol, and the polyethylene glycol has a number average molecular weight in the range of 200 g/mol to 600 g/mol.
3. The formulation of claim 1, wherein the formulation further comprises polyethylene glycol, and the polyethylene glycol has a number average molecular weight of 400 g/mol.
4. The formulation of any one of claims 1-3, wherein the anticoagulant is a solution comprising an alkali metal citrate salt, dextrose, and water.
5. The formulation of any one of claims 1-4, wherein the whole blood constitutes from 60% wt./wt. to 99% wt./wt. of the formulation.
6. The formulation of any one of claims 1-5, wherein the formulation comprises from 90 mL to 110 mL of whole blood.
7. The formulation of any one of claims 1-5, wherein the formulation comprises 10 mL to 20 mL of whole blood.
8. The formulation of any one of claims 1-5, wherein the formulation is in a form of a unit dose having a volume in a range from 50 mL to 200 mL.
9. The formulation of any one of claims 1-5, wherein the formulation is in a form of a unit dose having a volume in a range from 10 mL to 30 mL.
10. The formulation of any one of claims 1-9, wherein the formulation further comprises polyethylene glycol, and the polyethylene glycol is present at a concentration from 0.4 μL/mL to 4 μL/mL in the formulation.
11. The formulation of any one of claims 1-10, wherein the formulation further comprises N,N-dimethylacetamide, and the N,N-dimethylacetamide is present at a concentration from 0.2 μL/mL to 2 μL/mL in the formulation.
12. The formulation of any one of claims 1-11, wherein the formulation comprises at least 100 μg/mL of ABDNAZ.

13. The formulation of any one of claims 1-11, wherein the formulation comprises 10 µg/mL to 1 mg/mL of ABDNAZ.

14. The formulation of any one of claims 1-12, wherein the formulation comprises at least 150 µg/mL of ABDNAZ.